Mesa Biotech to Showcase New Molecular POC Testing Platform at the 2018 AACC Scientific Meeting

SAN DIEGO, July 18, 2018 /PRNewswire/ -- Mesa Biotech Inc., a privately-held, molecular diagnostic company that has developed an affordable PCR (polymerase chain reaction) testing platform designed specifically for point-of-care (POC) infectious disease diagnosis, today announced it will showcase its novel Accula^™ Flu A/Flu B test at the 70th Annual American Association of Clinical Chemistry Scientific Meeting & Clinical Lab Expo (AACC).  AACC is being held on July 29 – August 2, 2018 at McCormick Place in Chicago, Illinois. The Accula System, which will be on exhibit in booth 1878, obtained CE mark in the European Union (EU), as well as 501(k) clearance and CLIA waiver from the U.S. Food and Drug Administration (FDA) earlier this year.

"We are excited to be a part of this leading industry conference and showcase our recently launched testing platform to the more than 20,000 attendees," said Hong Cai, Co-founder and Chief Executive Officer, Mesa Biotech, Inc. "AACC is an important opportunity for us to connect with global leaders, highlight new assays under development and identify additional partnership opportunities."

A palm-sized, reusable dock with disposable test cassettes, the Accula System, offers the simplicity, convenience and procedural familiarity of traditional POC rapid immunoassays, while providing the superior sensitivity, specificity and information content of laboratory-based PCR testing. Test results are available in approximately 30 minutes to guide same-day treatment decisions. Accula Flu A/Flu B, the first commercialized test on the platform, is indicated for use with nasal swab collection that is less invasive than nasopharyngeal swabs and allows for a more comfortable specimen collection experience for the patient.

The Accula System is well positioned to expand into additional markets and indications. The handheld platform delivers flexibility in point of care, ranging from the physician's office and walk-in clinics to emergency rooms. The proprietary assay design allows for the rapid development of tests for human, agricultural, food pathogen, or genetic disease targets.

About Mesa Biotech Inc.

Mesa Biotech designs, develops, manufactures and commercializes next generation molecular diagnostic tests, bringing the superior diagnostic performance of nucleic acid PCR amplification to the point-of-care (POC). Mesa Biotech's Accula^™ System consists of a portable, palm-sized dock and disposable, assay-specific test cassettes. This patented system enables healthcare professionals to access actionable, laboratory-quality results at the POC with greater sensitivity and specificity than current infectious disease rapid immunoassay tests. For more information visit http://www.mesabiotech.com.

SOURCE Mesa Biotech Inc.

Related Links

http://www.mesabiotech.com